Trends and outcomes of breast surgical procedures in the Brazilian Unified Health System: a nationwide analysis (2015–2025)
DOI:
https://doi.org/10.29289/2594539420260019Palavras-chave:
breast neoplasms, mastectomy, breast-conserving surgery, hospital mortality, BrazilResumo
Introduction: Breast-related surgical care represents an important component of the Brazilian Unified Health System (SUS), but nationwide evidence on hospital activity and outcomes remains limited. Objective: This study aimed to analyze temporal trends, procedure distribution, in-hospital mortality, length of stay, and hospitalization reimbursement values between 2015 and 2025. Methods: This nationwide retrospective ecological study used aggregated Hospital Information System (SIH)/SUS data, in which records represent hospital admissions rather than unique patients. Admissions were identified through selected SIGTAP codes—the SUS Management System for the Table of Procedures, Medicines, Orthoses, Prostheses, and Special Materials—and classified as breast-conserving, mastectomy, reconstructive, or gender-affirming procedures. Isolated axillary lymphadenectomy codes were also screened but excluded from the primary analysis because these procedures are classified outside breast/oncologic surgery subgroups in SIGTAP and are compatible with non-breast diagnoses (e.g., cutaneous melanoma); they are described separately in Supplementary Table S1. Because some remaining codes—including the predominant breast-conserving procedure (sector resection/quadrantectomy)—are not exclusive to malignant breast disease, the analysis describes breast-related surgical admissions rather than a confirmed breast cancer cohort. Temporal trends were assessed using log-linear regression for the full period and for pre-specified sub-periods (2015–2019, 2020–2025, and 2021–2025). Mortality between mastectomy and breast-conserving admissions was described using absolute and relative frequencies, with the chi-square () test and unadjusted relative risk reported as secondary, exploratory analyses. Results: A total of 361,534 admissions were included in the primary analysis; an additional 4,275 admissions associated with isolated axillary lymphadenectomy were screened but excluded because of limited specificity for breast disease. Breast-conserving procedures accounted for 243,931 admissions (67.5%), mastectomy for 99,863 (27.6%), reconstructive procedures for 17,408 (4.8%), and gender-affirming mastectomies for 332 (0.1%). Overall, 224 in-hospital deaths occurred (0.062%). Crude in-hospital mortality was 0.033% for breast-conserving admissions (approximately 3.3 deaths per 10,000) and 0.143% for mastectomy admissions (approximately 14.3 deaths per 10,000); as a secondary, exploratory comparison, this corresponded to an unadjusted relative risk of 4.31 (95% confidence interval [95%CI] 3.28 to 5.66; =131.65; p<0.001), which should be interpreted cautiously given case-mix heterogeneity between groups. Admissions were essentially stable from 2015 to 2019 (annual percent change [APC]=−0.63%; 95%CI −1.35 to 0.09; p=0.070), decreased by 29.8% in 2020, and increased significantly from 2020 to 2025 (APC=+8.10%; 95%CI 2.36 to 14.16; p=0.017), without a significant linear trend across the full period (APC=−0.80%; 95%CI −3.81 to 2.31; p=0.573). For the complete screened cohort of 365,809 admissions, mean length of stay was 1.5 days, and total approved hospitalization reimbursement value was R$ 574.1 million. Conclusions: Breast-conserving procedures predominated among breast-related surgical admissions. Crude in-hospital mortality was higher for mastectomy than for breast-conserving admissions; because clinical indication, tumor stage, comorbidities, and other confounders were not available in the SIH/SUS dataset used for this analysis, this difference should be interpreted descriptively and not as a causal effect of the surgical procedure. These findings characterize hospital activity while acknowledging important limitations of administrative, diagnosis-blind data.
Downloads
Referências
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. https://doi.org/10.3322/caac.21834
2. Brasil. Instituto Nacional de Câncer. Estimativa 2026: incidência de câncer no Brasil. 2nd ed. rev. atual. Rio de Janeiro: INCA; 2026 [cited on 2026 Jun 22]. 168 p. Available from: https://ninho.inca.gov.br/jspui/handle/123456789/18062
3. Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159-82. https://doi.org/10.1016/j.annonc.2023.11.016
4. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023;21(6):594-608. https://doi.org/10.6004/jnccn.2023.0031
5. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-41. https://doi.org/10.1056/nejmoa022152
6. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-32. https://doi.org/10.1056/nejmoa020989
7. Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150(1):9-16. https://doi.org/10.1001/jamasurg.2014.2895
8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-16. https://doi.org/10.1016/s0140-6736(11)61629-2
9. Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-19 pandemic on cancer care. Nat Cancer. 2020;1(6):565-7. https://doi.org/10.1038/s43018-020-0074-y
10. Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21(8):1035-44. https://doi.org/10.1016/s1470-2045(20)30392-2
11. Brasil. Ministério da Saúde. Departamento de Informática do Sistema Único de Saúde. Produção Hospitalar (SIH/SUS) [Internet]. Brasília: Ministério da Saúde; [cited on 2026 Jun 22]. Available from: https://datasus.saude.gov.br/acesso-a-informacao/producao-hospitalar-sih-sus/
12. Brasil. Ministério da Saúde. Departamento de Informática do Sistema Único de Saúde. Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS – SIGTAP [Internet]. Brasília: Ministério da Saúde; [cited on 2026 Jun 22]. Available from: http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jsp
13. Brasil. Conselho Nacional de Saúde. Resolução nº 510, de 7 de abril de 2016 [Internet]. Brasília: Conselho Nacional de Saúde; 2016 [cited on 2026 Jun 22]. Available from: https://www.gov.br/conselho-nacional-de-saude/pt-br/atos-normativos/resolucoes/2016/resolucao-no-510.pdf/view
14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-7. https://doi.org/10.1016/S0140-6736(07)61602-X
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Pedro Carrión Carvalho, Beatriz Luana Baratter do Carmo, Giovanna Marchetti, Camylle Hawerroth Henrique, Martina Werner Siebert, Mariana Vieira Zanatta, Vinicius Goedert Foguesatto

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.






